Table 1 Baseline demographic and clinical characteristics of 24 mCRC patients
Characteristics | N = 24 patients n (%) |
|---|---|
Age (year) | |
Median (range) | 68(61–77) |
Gender | |
Male | 9 (37.5%) |
Female | 15 (62.5%) |
ECOG performance status | |
0 | 5 (20.8%) |
1 | 16 (66.7%) |
2 | 3 (12.5%) |
Primary tumor location | |
Colon | 15 (62.5%) |
Right-side | 8 (33.3%) |
Left-side | 7 (29.2%) |
Rectum | 9 (37.5%) |
Whether the primary tumor is resected | |
Resected | 21 (87.5%) |
Not resected | 3 (12.5%) |
Type of metastasis | |
With liver or lung metastasis | 22 (91.7%) |
With only liver metastasis | 6 (25.0%) |
With only lung metastasis | 7 (29.2%) |
With liver and lung metastasis | 9 (37.5%) |
With bone metastasis | 3 (12.5%) |
With brain metastasis | 1 (4.2%) |
With distant lymph nodes metastasis | 11 (45.8%) |
With peritoneum metastasis | 4 (16.7%) |
With other organs metastasis | 2 (8.3%) |
Previous lines of chemotherapy | |
Two lines | 13 (54.2%) |
Three or more lines | 11 (45.8%) |
Previous targeted therapy | |
Bevacizumab | 15 (62.5%) |
Cetuximab | 3 (12.5%) |
With Bevacizumab and Cetuximab | 3 (12.5%) |
Without previous targeted therapy | 6 (25.0%) |
Combination immunization agents | |
Sintilimab | 12 (50.0%) |
Carrelizumab | 6 (25.0%) |
Nivolumab | 2 (8.3%) |
Toripalimab | 2 (8.3%) |
Pembrolizumab | 1 (4.2%) |
Tislelizumab | 1 (4.2%) |
Whether previous exposure to regorafenib | |
Exposure to regorafenib | 8 (33.3%) |
No exposure to regorafenib | 16 (66.7%) |
Whether with the local treatment | |
With the local treatment | 3 (12.5%) |
Without the local treatment | 21 (87.5%) |
Gene mutation status | |
RAS and BRAF wild-type | 5 (20.8%) |
K-RAS mutant | 16 (66.7%) |
BRAF mutant | 1 (4.2%) |
Unknow | 2 (8.3%) |
MMR or MSI status | |
pMMR or MSS | 19 (79.2%) |
dMMR or MSI-H | 1 (4.2%) |
Unknown | 4 (16.7%) |